Similar articles

• Case-control studies to assess vaccine effectiveness? Yes, but not this way.

  Bernaola E, Herranz M, Clerigue N, Gil F. Bernaola E, et al. Clin Infect Dis. 2007 Nov 1;45(9):1240-1; author reply 1242-3. doi: 10.1086/522286. Clin Infect Dis. 2007. PMID: 17918091 No abstract available.
• Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.

  Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, Anglim AM. Farr BM, et al. Arch Intern Med. 1995 Nov 27;155(21):2336-40. Arch Intern Med. 1995. PMID: 7487259
• Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.

  Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA, Rodriguez-Blanco T, Salsench E, Fuentes CM; EPIVAC Study Group. Vila-Corcoles A, et al. BMC Infect Dis. 2010 Mar 18;10:73. doi: 10.1186/1471-2334-10-73. BMC Infect Dis. 2010. PMID: 20298596 Free PMC article.
• Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.

  Reinert RR, Paradiso P, Fritzell B. Reinert RR, et al. Expert Rev Vaccines. 2010 Mar;9(3):229-36. doi: 10.1586/erv.10.6. Expert Rev Vaccines. 2010. PMID: 20218848 Review. No abstract available.
• Experience with pneumococcal conjugate vaccine in Norway.

  Aaberge IS. Aaberge IS. Expert Rev Vaccines. 2009 Feb;8(2):159-65. doi: 10.1586/14760584.8.2.159. Expert Rev Vaccines. 2009. PMID: 19196196 Review.